This study is looking into a new eye drop treatment called EYED-002, which contains human insulin, for people with open-angle glaucoma. Glaucoma is an eye condition that can damage your optic nerve. The study wants to find out if EYED-002 is safe and how well it works. You would receive either a low dose (721 U/mL) or a high dose (1442 U/mL) of EYED-002, or a placebo (a drop without active insulin). The study is open to adults aged 18 to 90 who have been diagnosed with glaucoma. The main goal is to track any side effects, but researchers will also look at how the treatment affects your vision and eye health. There are 90 participants planned for this study.

Study design

This study is designed in phases, starting with testing different doses of EYED-002, then moving to a masked, randomized, placebo-controlled phase. This means some participants will receive the active drug and others a placebo, without knowing which they are getting. There are 90 participants planned.

What's involved

Participants will receive one drop of EYED-002 or a placebo in one eye daily. For some groups, this will be in-clinic, and for others, it will be at home with quarterly visits for 12 months. Safety will be monitored for up to 27 months.

Compensation

Not stated in the trial record.

Follow-up

Your safety will be monitored from the time you give consent until the end of your participation, which could be up to 27 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.